Physician
Hematology
Dr. Edward A. Copelan, MD
|
|
Give Review
Edward Copelan is an expert in the field of Hematology. He attended Tufts University School of Medicine. Tufts University School of Medicine has a rank of 49 in research and a 52 in primary care He received awards:"America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification" and "Northern Ohio Live". Edward A. Copelan is a published MD. He has 44 papers published. The most current publication "Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies." Edward Copelan accepts Medicare.
Publications
- Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies.
- Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Lingering Uncertainties and Emerging Possibilities.
- Racial differences in allogeneic hematopoietic cell transplantation outcomes among African Americans and whites.
- Cyclosporine in combination with mycophenolate mofetil versus methotrexate for Graft versus host disease prevention in myeloablative HLA-identical sibling donor alloge...
- Comparison of Outcomes of Allogeneic Transplantation for CML with Cyclophosphamide in Combination with IntraVenous Busulfan, Oral Busulfan or TBI.
- Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic cell transplantation.
- Risk factors for vancomycin-resistant enterococcus bacteremia and its influence on survival after allogeneic hematopoietic cell transplantation.
- SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed Acute myeloid leukaemia.
- Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations.
- Long-term follow-up of a prospective randomized trial comparing CYA and MTX with CYA and mycophenolate mofetil for GVHD prophylaxis in myeloablative sibling donor hema...
- Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.
- Providing Personalized Prognostic Information for Adult Leukemia Survivors.
- Better Leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared to TBI.
- Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhi...
- Validating the positive impact of in-hospital lay care-partner support on patient survival in allogeneic BMT: a prospective study.
- Unrelated donor allogeneic transplantation after failure of autologous transplantation for Acute myeloid leukemia: a study from the cibmtr.
- Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience.
- Defining Incidence, Risk Factors, and Impact on Survival of Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myelo...
- Sustained disease-free survival achieved with withdrawal of immunosuppression after rapid relapse of myelodysplastic Syndrome following myeloablative allogeneic hemato...
- SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic Syndromes.
- Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis.
- Concise review: the role of hematopoietic stem cell transplantation in the treatment of Acute myeloid leukemia.
- Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed Acute lymphoblastic leukemia.
- Risk Factors for 30-Day Hospital Readmission Following Myeloablative Allogeneic Hematopoietic Cell Transplantation (AlloHCT).
- Can G-CSF cause Leukemia in hematopoietic stem-cell donors?
- Acute myeloid leukemia: when to transplant in first complete remission.
- Late mortality and relapse following BuCy2 and HLA-identical sibling marrow transplantation for chronic myelogenous Leukemia.
- Time from diagnosis to treatment initiation predicts survival in younger, but not older, Acute myeloid leukemia patients.
- Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid Leukemia.
- Unrelated donor transplants in adults with Philadelphia-negative Acute lymphoblastic leukemia in first complete remission.
- Hematopoietic stem cell transplantation in adults with Acute myeloid leukemia.
- Hematopoietic stem cell transplantation in multiple Myeloma.
- Thalidomide-induced fulminant hepatic failure.
- Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic Anemia after failure of immunosuppressive therapy.
- A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allograf...
- High disease burden is associated with poor outcomes for patients with Acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation.
- Chronic myelogenous Leukemia.
- Unrelated donor marrow transplantation for B-cell chronic lymphocytic Leukemia after using myeloablative conditioning: results from the Center for International Blood ...
- Syngeneic vs. allotransplantation in chronic myeloid Leukemia: all's well that ends well.
- Dose modification protocol using intraVenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation i...
- Autologous stem cell transplantation for non-Hodgkin's Lymphoma.
- Treatment options in chronic myelogenous Leukemia.
- Breast Cancer cell contamination of blood stem cell products in patients with metastatic breast Cancer: predictors and clinical relevance.
Schools
Tufts University
Ohio State University Hospital
Ohio State University
Procedures Preformed
- Bone Marrow Transplant
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- HPC Transplantation (Stem Cell Transplant)
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Northern Ohio Live
Education
-
Ohio State University Hospital -
Tufts University School of Medicine
Hospital
-
Cleveland Clinic
Drug Facts
| NPI NUMBER | 1962417451 | |
| NPPES Provider LastName | COPELAN | |
| NPPES Provider FirstName | EDWARD | |
| NPPES Provider ZIPCode | 282042839 | |
| NPPES Provider State | NC | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 75.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1962417451 |
| Last Name Of The Provider | COPELAN |
| First Name Of The Provider | EDWARD |
| View All |
Similar Doctors
|
|
Dr. Nilanjan Ghosh, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kwabena Osei-Boateng, MD |
|
|
Dr. Belinda R. Avalos, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Manisha Bhutani, MD
This Doctor is OpenDoctor Recommended.
|